Japan Approves Insurance Coverage For Three Diagnostics
This article was originally published in PharmAsia News
The Central Social Medical Insurance Agency (Chuikyo) April 21 approved insurance coverage for three diagnostic items. The council approved price listing for MESACUP anti-RNA polymerase III test for systemic scleroderma at ¥1,700, citing a high sensitivity in systemic scleroderma diagnosis and efficacy compared to current diagnostics. The test is developed by Medical and Biological Laboratories. In addition, two fatty acid binding protein diagnostics for acute myocardial infarction, developed separately by DS Pharma Biomedical and Biolinks, were priced at ¥1,500. Both diagnostics are able to obtain rapid results compared to current testing. (Click here for more - Japanese language)"Chuikyo Approves Medical Insurance For Three Diagnostics Including Systemic Scleroderma Testing" - Chemical Daily (4/14/2010)
You may also be interested in...
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.
Clinical Trials: Industry Navigating Alternative Ways Of Delivering Investigational Drugs During Pandemic
New approaches include delivering study drug from a clinical site directly to a patient’s house through a courier service, as well as use of drones and automated dispensing units; future trials could see a mix of delivery approaches.
Benefits of the BCMA-directed antibody-drug conjugate outweigh its ocular risks in heavily pretreated multiple myeloma patients, Oncologic Drugs Advisory Committee says at the conclusion of a virtual meeting beset by technical problems.